YAbS: The Antibody Society’s antibody therapeutics database
mAbs,
Год журнала:
2025,
Номер
17(1)
Опубликована: Фев. 27, 2025
Therapeutic
antibodies
have
gained
prominence
in
recent
years
due
to
their
precision
targeting
specific
diseases.
As
these
molecules
become
increasingly
essential
modern
medicine,
comprehensive
data
tracking
and
analysis
are
critical
for
advancing
research
ensuring
successful
clinical
outcomes.
YAbS,
The
Antibody
Society's
Therapeutics
Database,
serves
as
a
vital
resource
monitoring
the
development
progress
of
therapeutic
antibodies.
database
catalogs
detailed
information
on
over
2,900
commercially
sponsored
investigational
antibody
candidates
that
entered
study
since
2000,
well
all
approved
therapeutics.
Data
late-stage
pipeline
therapeutics
regulatory
review
or
(over
450
molecules)
openly
accessible
(https://db.antibodysociety.org).
Antibody-related
includes
molecular
format,
targeted
antigen,
current
status,
indications
studied,
timeline
antibodies,
geographical
region
company
sponsors.
Furthermore,
supports
in-depth
industry
trends
analysis,
facilitating
identification
innovative
developments
assessment
success
rates
within
field.
This
is
continually
updated
refined,
providing
invaluable
insights
researchers,
clinicians,
professionals
engaged
development.
Язык: Английский
Proof of Concept for the Single-Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein
Опубликована: Янв. 1, 2025
Язык: Английский
Leveraging HER2-targeted Biparatopic Antibodies in Solid Tumors
Pharmacological Research,
Год журнала:
2025,
Номер
214, С. 107687 - 107687
Опубликована: Март 5, 2025
Biparatopic
antibodies
(bpAbs),
which
target
non-overlapping
epitopes
on
the
same
antigen,
offer
unique
mechanisms
of
action
and
therapeutic
applications
that
surpass
those
conventional
monospecific
antibodies.
These
distinctive
properties
have
positioned
bpAbs
as
effective
agents
in
treatment
cancer
infectious
diseases,
especially
cases
where
current
treatments
face
limitations.
Among
these,
HER2-targeted
shown
significant
improvements
survival
outcomes
for
patients
with
solid
tumors
depend
HER2
signaling.
However,
a
comprehensive
understanding
their
clinical
impact,
action,
limitations
use
remains
lacking.
Here,
we
review
contrast
performance
well-established
use,
focus
associated
limitations,
potential
combination
strategies.
We
also
highlight
emerging
investigational
bpAbs-based
promise
HER2-positive
cancers.
advancements
may
lead
to
enhanced
options
potentially
broaden
scope
therapy.
Язык: Английский
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
American Society of Clinical Oncology Educational Book,
Год журнала:
2025,
Номер
45(3)
Опубликована: Апрель 8, 2025
Bispecific
antibodies
(bsAbs)
have
emerged
as
a
novel
class
of
therapeutics,
offering
dual-targeting
strategy
to
enhance
the
therapeutic
efficacy
monoclonal
antibodies,
which
is
often
limited
by
tumor
heterogeneity
and
occurrence
resistance
mechanisms.
By
simultaneously
engaging
two
distinct
antigens
or
pathways,
bsAbs
disrupt
multiple
signaling
cascades
simultaneously,
preventing
escape
mechanisms
more
durable
response.
Furthermore,
they
can
optimize
immune
activation,
improving
cell
recruitment
strategies.
In
particular,
T-cell
engager
facilitate
cell–mediated
destruction
linking
T
cells
antigens.
Instead,
dual
checkpoint
inhibitors
(CPIs)
activation
blocking
inhibitory
signals.
Additionally,
targeting
growth
factors
receptor
tyrosine
kinases
offer
solutions
for
overcoming
drug
in
solid
tumors.
Although
shown
remarkable
success
hematologic
malignancies,
their
expansion
into
tumors
faces
key
challenges,
including
heterogeneity,
penetration,
risk
on-target,
off-tumor
toxicities.
Addressing
these
challenges
requires
innovative
engineering
strategies,
optimized
delivery
mechanisms,
careful
patient
selection
maximize
benefit
while
mitigating
adverse
effects.
The
clinical
trials
has
led
approval
both
with
numerous
agents
development.
Combination
strategies
chemotherapy,
targeted
agents,
CPIs
could
represent
promising
further
expand
potential.
As
research
progresses,
are
expected
play
role
reshaping
future
precision
oncology,
effective
tailored
treatment
options.
Язык: Английский